Rudolf Übelhart is Director for Research and Development at Heidelberg ImmunoTherapeutics and responsible for managing early research and discovery projects. He joined the company in 2020 with more than 12 years of professional experience in molecular immunology, immuno-oncology, synthetic biology, and the development of antibody-based therapeutics. Before joining Heidelberg ImmunoTherapeutics, he was a scientific group leader at the German Cancer Research Center (DKFZ) and at the National Center for Tumor Diseases (NCT) in Heidelberg where he focused on the development of CAR-T cell therapeutics for treating cancer. Earlier during his academic career at the Max-Planck-Institute of Immunobiology and Epigenetics in Freiburg and the University Hospital in Ulm, he worked in the field of B-cell antigen receptors and B-cell development and characterized the mechanism of autonomous B cell receptor signalling in Chronic Lymphocytic Leukemia (CLL) patients. Rudolf Übelhart published in top peer-review journals including Nature and Nature Immunology. He obtained his PhD from the University of Freiburg and was a lecturer in Immunology at the University of Ulm.